MTREX

Across TCGA pan-cancer cohorts, MTREX mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MTREX data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MTREX mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTREX expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where MTREX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.680	0.905	<.001	37	view →
LSCC	DFS	Tertile	II,III,IV	0.910	0.595	.014	14	view →
PDAC	DFS	Tertile	IV	0.741	0.203	.024	5	view →
GBM	DFS	Tertile	All	0.512	0.259	.049	2	view →
LUAD	DFS	Tertile	III,IV	0.723	0.210	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTREX–CCRCC (DFS)

Open the CCRCC breakdown →